Vivos Inc Revenue Growth Rates (RDGL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vivos Inc  (RDGL)
 

RDGL's Revenue Growth by Quarter and Year

Vivos Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RDGL/growth
https://api.csimarket.com/api/v1/companies/RDGL/fundamentals
https://api.csimarket.com/api/v1/companies/RDGL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
RDGL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.03
2nd Quarter June 0.04
1st Quarter March 0.02
FY 0.09

RDGLs Annual Revenue
Vivos Inc's Revenue in the fiscal year 2025 $ 0.07 millions
Vivos Inc's Revenue in the fiscal year 2024 $ 0.03 millions
Vivos Inc's Revenue in the fiscal year 2023 $ 0.02 millions
Vivos Inc's Revenue in the fiscal year 2022 $ 0.04 millions
Vivos Inc's Revenue in the fiscal year 2021 $ 0.01 millions




RDGL Revenue third quarter 2026 Y/Y Growth Comment
Vivos Inc achieved in the third quarter 2026, above Company average Revenue rise of 44.5% year on year, to $ 0.03 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 105 other companies have achieved higher Revenue growth. While Vivos Inc' s Revenue jump of 44.5% ranks overall at the positon no. 2035 in the third quarter 2026.


RDGL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 44.5 %
2nd Quarter June 33.33 %
1st Quarter March -
FY   -

Financial Statements
Vivos Inc's third quarter 2026 Revenue $ 0.03 millions RDGL's Income Statement
Vivos Inc's third quarter 2025 Revenue $ 0.02 millions Quarterly RDGL's Income Statement


RDGL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -27.75 %
2nd Quarter June 100 %
1st Quarter March -
FY (Year on Year)   -


Back to RDGL Growth rate Comparisons >> Back to RDGL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #106
Healthcare Sector #297
Overall #2035

Revenue Y/Y Growth Statistics
High Average Low
62.74 % 19.01 % -18.76 %
(Mar 31 2026)   (Jun 30 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #106
Healthcare Sector #297
Overall #2035
Revenue Y/Y Growth Statistics
High Average Low
62.74 % 19.01 % -18.76 %
(Mar 31 2026)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Vivos Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1217.3 % 81.13 % -100 %
(Dec 31 2025)  


RDGL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Vivos Inc disclosed fall in Revenue from the second quarter by -27.75% to $ 0.03 millions, from $ 0.04 millions achived in the previous reporting period.

But that's not important problem, as Vivos Inc's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Vivos Inc's Revenue growth quarter on quarter, overall rank is 129.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #8
Healthcare Sector #42
Overall #129
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #8
Healthcare Sector #42
Overall #129
Revenue Q/Q Growth Statistics
High Average Low
1217.3 % 81.13 % -100 %
(Dec 31 2025)  


RDGL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Vivos Inc disclosed fall in Revenue from the second quarter by -27.75% to $ 0.03 millions, from $ 0.04 millions achived in the previous reporting period.

But that's not important problem, as Vivos Inc's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Vivos Inc's Revenue growth quarter on quarter, overall rank is 129.


Vivos Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.09
Y / Y Revenue Growth (TTM) 86.01 %
Year on Year Revenue Growth Overall Ranking # 212
Seqeuential Revenue Change (TTM) 17.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 2035


Cumulative Revenue growth Comment
Vivos Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 86.01% year on year, to $ 0 millions if the fiscal year would have ended in Sep 30 2026.
Vivos Inc's trailing twelve months Revenue growth was higher than company's average 19.01% and higher than 62.74% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 17.89 % from $0.08 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at19.01%.

In the Healthcare sector 65 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 212.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 106
Healthcare Sector # 66
Overall # 212

Revenue TTM Y/Y Growth Statistics
High Average Low
62.74 %
 19.01 %
-18.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 297
S&P 500 # 2035
Cumulative Revenue growth Comment
Vivos Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 86.01% year on year, to $ 0 millions if the fiscal year would have ended in Sep 30 2026.
Vivos Inc's trailing twelve months Revenue growth was higher than company's average 19.01% and higher than 62.74% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 17.89 % from $0.08 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at19.01%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 17.89 % increase from $0.08 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 65 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 212.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 106
Healthcare Sector # 66
Overall # 212

Revenue TTM Y/Y Growth Statistics
High Average Low
62.74 %
19.01 %
-18.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 297
S&P 500 # 2035




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RDGL's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions


About Vivos Inc Revenue Growth Rates (RDGL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vivos Inc (CIK 1449349).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-051418
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vivos Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.